Eris Lifesciences vs Akums Drugs vs Innova Captab: Which Stock Should You Track
- September 28, 2026
- Posted by: Harsh Piplani
- Category: Market
Eris Lifesciences PE 26.27, mkt cap Rs 17,490 crore. Akums Drugs and Pharmaceuticals PE 44.03, mkt cap Rs 12,891 crore. Innova Captab PE 47.62, mkt cap Rs 7,336 crore.
Quick Answer
Eris Lifesciences vs Akums Drugs and Pharmaceuticals vs Innova Captab is a side-by-side comparison of three companies from the Pharma Formulations space. On this comparison, Eris Lifesciences carries a market capitalisation of about Rs 17,490 crore against Rs 12,891 crore for Akums Drugs and Pharmaceuticals and Rs 7,336 crore for Innova Captab, with return on equity of 15.87%, 7.70% and 12.92% respectively. Each company’s numbers are presented here without a declared better pick, since the right stock depends on an investor’s own criteria.
Eris Lifesciences vs Akums Drugs and Pharmaceuticals vs Innova Captab starts with the core numbers most investors compare within the Pharma Formulations segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.
All three names sit in the Pharma Formulations bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.
Click Here – Get Free Investment Predictions
Eris Lifesciences, Akums Drugs and Pharmaceuticals and Innova Captab: Company Overview
Eris Lifesciences is a listed Indian company in the Pharma Formulations space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Akums Drugs and Pharmaceuticals is a listed Indian company in the Pharma Formulations space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Innova Captab is a listed Indian company in the Pharma Formulations space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Eris Lifesciences vs Akums Drugs and Pharmaceuticals vs Innova Captab: Valuation and Profitability Snapshot
| Metric | Eris Lifesciences | Akums Drugs and Pharmaceuticals | Innova Captab |
|---|---|---|---|
| Market Cap (approx.) | Rs 17,490 crore | Rs 12,891 crore | Rs 7,336 crore |
| PE Ratio (TTM) | 26.27 | 44.03 | 47.62 |
| PB Ratio | 4.48 | 3.89 | 6.73 |
| Return on Equity (ROE) | 15.87% | 7.70% | 12.92% |
| EPS (TTM, Rs) | 47.98 | 18.60 | 26.92 |
| Dividend Yield | 0.57% | 0.36% | 0.16% |
| Debt to Equity | 0.60 | 0.05 | 0.32 |
| Book Value per Share (Rs) | 281.30 | 210.57 | 190.61 |
Check the Univest Screener for Live Data
On valuation, Eris Lifesciences trades at a PE of 26.27 and a PB of 4.48, Akums Drugs and Pharmaceuticals at a PE of 44.03 and a PB of 3.89, while Innova Captab trades at a PE of 47.62 and a PB of 6.73. On return on equity, the three post 15.87%, 7.70% and 12.92% respectively, and on dividend yield they stand at 0.57%, 0.36% and 0.16%.
Eris Lifesciences vs Akums Drugs and Pharmaceuticals vs Innova Captab: Latest Quarterly Results
| Company | Latest Quarter Revenue | Latest Quarter Net Profit | YoY Change (Revenue) | QoQ Change (Revenue) |
|---|---|---|---|---|
| Eris Lifesciences | Rs 875.64 crore | Rs 143.32 crore | +12.9% | +15.4% |
| Akums Drugs and Pharmaceuticals | Rs 1,197.01 crore | Rs 100.98 crore | +13.9% | +0.3% |
| Innova Captab | Rs 472.86 crore | Rs 44.13 crore | +32.8% | +5.2% |
Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter.
Download the Univest iOS App or Univest Android App to track Eris Lifesciences, Akums Drugs and Pharmaceuticals and Innova Captab live prices.
What Should Investors Look at Beyond These Numbers?
Beyond the metrics above, investors comparing these three pharma formulations names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and any sector-specific regulatory developments, since a single-quarter snapshot can shift quickly.
Conclusion
Eris Lifesciences vs Akums Drugs and Pharmaceuticals vs Innova Captab highlights how differently three companies in the same pharma formulations segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information as of September 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Eris Lifesciences vs Akums Drugs and Pharmaceuticals vs Innova Captab
What is the market cap difference between Eris Lifesciences, Akums Drugs and Pharmaceuticals and Innova Captab?
Ans. As of September 2026, Eris Lifesciences has a market cap of approximately Rs 17,490 crore, Akums Drugs and Pharmaceuticals is at approximately Rs 12,891 crore, and Innova Captab is at approximately Rs 7,336 crore.
Which of the three has the highest PE ratio?
Ans. Among Eris Lifesciences, Akums Drugs and Pharmaceuticals and Innova Captab, the PE ratios stand at 26.27, 44.03 and 47.62 respectively as of September 2026.
Which of the three has the highest ROE?
Ans. Eris Lifesciences, Akums Drugs and Pharmaceuticals and Innova Captab post ROE of 15.87%, 7.70% and 12.92% respectively as of September 2026.
Which of these three stocks pays the highest dividend yield?
Ans. Eris Lifesciences, Akums Drugs and Pharmaceuticals and Innova Captab carry dividend yields of 0.57%, 0.36% and 0.16% respectively.
What is the debt to equity ratio for Eris Lifesciences, Akums Drugs and Pharmaceuticals and Innova Captab?
Ans. Eris Lifesciences carries a debt to equity of 0.60, Akums Drugs and Pharmaceuticals of 0.05, and Innova Captab of 0.32.
Which of the three trades at the highest price to book value?
Ans. Eris Lifesciences, Akums Drugs and Pharmaceuticals and Innova Captab trade at price to book ratios of 4.48, 3.89 and 6.73 respectively.
Is one of Eris Lifesciences, Akums Drugs and Pharmaceuticals or Innova Captab better than the others?
Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor’s own criteria and research.
